Recruiting × INDUSTRY × Leukemia, Myeloid, Acute × Clear all AUGMENT-101
Phase 1/2 Recruiting
447 enrolled 2 FDA
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Phase 2/3 Recruiting
316 enrolled
MOMENTUM
Phase 1/2 Recruiting
84 enrolled
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Phase 1 Recruiting
178 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
CROSSCHECK-001
Phase 1 Recruiting
72 enrolled
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Phase 1 Recruiting
420 enrolled
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Phase 1 Recruiting
115 enrolled
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Phase 1 Recruiting
10 enrolled
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Phase 1/2 Recruiting
33 enrolled
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
Recruiting
165 enrolled
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Phase 1 Recruiting
18 enrolled
TRILLIUM
Phase 2 Recruiting
83 enrolled
A Study of BGB-11417 in Participants With Myeloid Malignancies
Phase 1/2 Recruiting
260 enrolled
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Phase 1 Recruiting
78 enrolled
Aquarius
Recruiting
550 enrolled
QuANTUM-WILD
Phase 3 Recruiting
700 enrolled
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Phase 1/2 Recruiting
12 enrolled
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1 Recruiting
300 enrolled
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Phase 1 Recruiting
76 enrolled
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Phase 1 Recruiting
100 enrolled
REVEAL-ND NPM1
Phase 3 Recruiting
468 enrolled
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Phase 1/2 Recruiting
225 enrolled
MO-TRANS
Phase 3 Recruiting
366 enrolled
cAMeLot-1
Phase 1/2 Recruiting
400 enrolled
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 Recruiting
60 enrolled
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Phase 1 Recruiting
48 enrolled
cAMeLot-2
Phase 3 Recruiting
600 enrolled
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1 Recruiting
130 enrolled
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
Phase 4 Recruiting
100 enrolled
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
Phase 1 Recruiting
50 enrolled
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Phase 1 Recruiting
120 enrolled
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Phase 1/2 Recruiting
29 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Phase 1/2 Recruiting
70 enrolled
RAPID
Phase 1 Recruiting
40 enrolled
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Phase 2/3 Recruiting
312 enrolled
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Phase 1/2 Recruiting
49 enrolled
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Phase 2 Recruiting
130 enrolled
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
171 enrolled
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Phase 1 Recruiting
36 enrolled
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Phase 3 Recruiting
486 enrolled
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
72 enrolled
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
263 enrolled 1 FDA
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
124 enrolled
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Recruiting
105 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/2 Recruiting
70 enrolled
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
78 enrolled
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/2 Recruiting
458 enrolled